27,900 results
The stock has more than doubled since I suggested investors buy ... of which results from the ATA188 study in patients with progressive MS and phase 3 tab-cel results in the first half of 2019 are primarily on my radar. It's also worth …
The Juno acquisition added JCAR017 (lisocabtagene maraleucel; liso-cel) to Celgene’s lymphoma pipeline ... Celgene currently carries a Zacks Rank #4 …
Cellcom Israel's shares are traded both on the New York Stock Exchange (CEL) and the Tel Aviv Stock Exchange (CEL). For additional information please visit the Company's website http://investors.cellcom.co.il.
Trending on Bing
CEL-SCI is a Phase 3 cancer immunotherapy company. When it comes to cancer immunotherapy, CEL-SCI believes it is most logical to boost the patient’s immune system while it is still intact in order to have the greatest possible impact on …
Presented positive interim tab-cel™ results from a multicenter expanded access protocol ... along with the $131.4 …
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or …
Cellcom Israel's shares are traded both on the New York Stock Exchange (CEL) and the Tel Aviv Stock Exchange (CEL). For additional information please visit the Company's website http://investors.cellcom.co.il.